Differences Ratio Level Soluble FMS-Like Tyrosine Kinase-1 and Placental Growth Factor Early And Late Onset on Preeclampsia and Normal Pregnancy

Ria Andina; Yanwirasti Yanwirasti; Defrin Defrin

doi:10.25077/jom.3.1.83-92.2018

Differences Ratio Level Soluble FMS-Like Tyrosine Kinase-1 and Placental Growth Factor Early And Late Onset on Preeclampsia and Normal Pregnancy

DOI: https://doi.org/10.25077/jom.3.1.83-92.2018

Author(s)

Ria Andina (Andalas University)
Yanwirasti Yanwirasti (Andalas University)
Defrin Defrin (RSUP DR. M. Djamil,)

Abstract

Preeclampsia is a major maternal morbidity and mortality worldwide including in Indonesia. PIGF concentrations were found to be lower and sFlt-1 to be higher in patients with preeclampsia than normal pregnancy. Futher, this factor has been proposed as a parameter that can help identify women with potentially preeclampsia.This study aims todeterminethe differences ratio level soluble rate fms-like tyrosine kinase-1 and placental growth factor early and late onset on preeclampsia and normal pregnancy. The cross sectional study design was conducted in RSUP M.Djamil, Rasidin Hospital, Reksodiwiryo Hospital and Biomedical Laboratory of Andalas University from July 2017 until January 2018. The sample of this study was pregnant women>20-42 weeks pregnancy totalling 80 people by consecutive sampling.Sample was divided into 3 groups. SFlt-1 and PlGF levels tested using ELISA test. Test the normality of data by Kolmogrov-Smirnov test by using unpaired T test.The results showed median sFLT-1 levels in the early onset group with normal pregnancy with p= 0,88, median sFLT-1 levels in the late onset group with normal pregnancy with p= 0,01 and median levels of sFLT-1 in the early onset group with late onset with p= 0.34. Mean of PlGF in the early onset group with normal pregnancy with p=0,30, mean of PlGF in the late onset group with normal pregnancy with p= 0.63, and mean of PlGF in the early onset group with late onset with p = 0.27. The conclusion of this study was that there was a difference ratio level Soluble Fms-Like Tyrosine Kinase-1 late onset in preeclampsia and normal pregnancy.

Full Text:

PDF

References

Jeyabalan A. Epidemiology of preeclampsia: Impact of obesity. NIH Public Access. 2013 Oct;71(1):18-25.

Rahmi L, Herman RB, Yusrawati. Perbedaanreratakadar Soluble Fms-Like Tyrosine Kinase-1 (Sflt-1) Serum padaPenderita Early Onset, Late Onset PreeklampsiaBerat/ EklamspiadanKehamilan Normal. JurnalFakultasKedokteranUniversitasAndalas. 2016 Feb;5(1):41-48.

Osungbade KO, Ige OK. Public Health Perspectives of Preeclampsia in Developing Countries:Implication for Health System Strengthening. Journal of Pregnancy, 2011 Jan;2011(1):1-6.

Kementerian Kesehatan Republik Indonesia. (2016). Profil Kesehatan Indonesia Tahun 2015. Jakarta: Kementerian Kesehatan Republik Indonesia.

Dinas Kesehatan Kota Padang. (2015). Profil Kesehatan kota Padang Tahun 2015. Padang: Dinas Kesehatan Kota Padang.

Lyall, F,Belfort M. Pre-eclampsia: Etiology and Clinical Practice. New York: Cambridge University Press; 2007. 1 p.

Akolekar R, de CJ, Foidart J, Munaut C, Nicolaides KH. Maternal plasma soluble fms-like tyrosine kinase-1 and free vascular endothelial growth factor at 11 to 13 weeks of gestation in preeclampsia. PrenatDiagn. 2010 Mar;30(3):191-197.

Parra-Cordero M, Rodrigo R, Barja, P, Bosco C, Rencoret G, Sepuvelda-Martinez A, et al. Prediction of early and late pre-eclampsia from maternal characteristics, uterine artery Doppler and markers of vasculogenesis during first trimester of pregnancy. Ultrasound Obstet Gynecol. 2013 May;41(2):538–544.

Wikstrom AK. Biochemical and Epidemiological Studies of Early-Onset and Late-Onset Pre-Eclampsia. Dissertation, Uppsala University, Faculty of Medicine, Swedish. 2007 Nov;282:21-59.

Beňovská M, Opluštilová A, Pinkavová J, Hodická Z,Čermáková Z. The New Possibilities in Early Diagnosis of Preeclampsia by Soluble fms-Like TyrosineKinase-1 and Placental Growth Factor in 16–20 Weeks Gestation. American Society for Clinical Pathology. 2018 Mar;49(2):112-117.

Luealon P, Phupong V. Risk Factor of preeclampsia in Thai Woman. J Med Assoc Thai [Internet]. 2010 Jun [cited 2018 April];93(6):661-666. Available from: http://jmat.mat.or.th/index.php/jmat/article/`viewfile/302/302

Erez O, Romero R, Maymon E, Chaemsaithong P, Done B, Pacora P, et al. The prediction of late-onset preeclampsia: Results from a longitudinal proteomics study. PLOS ONE.2017 Jul;12(7):1-28.

Villa PM, Hamalainen E, Mmortality rate in IndonesiaA, Raikkonen K, Pesonen AK, Taipale P, et al. Vasoactive agents for the prediction of early- and late-onset preeclampsia in a high-risk cohort. BMC Pregnancy and Childbirth. 2013 Mei;13:110.

Huppertz, B. Placental Origins of Preeclampsia: Challenging the Current Hypothesis. Hypertension. 2008 Apr;51(4):970-975.

NanjoS, Minami S, Mizoguchi M, Yamamoto M, Yahata T, Toujima S, et al. Levels of serum-circulating angiogenic factors within 1 week prior to delivery are closely related to conditions of pregnant women with pre-eclampsia, gestational hypertension, and/or fetal growth restriction. The Journal of Obstetrics and Gynaecology Study. 2017 Des;43(12):1805-1814.

Perni U, Sison C, Sharma V, Helseth G, Hawfield A, Suthanthiran M, et al. Angiogenic Factors in Superimposed Preeclampsia A Longitudinal Study of Women With Chronic Hypertension During Pregnancy. Hypertension. 2012 Mar;59:740-746.

Lynch A, Murphy J, Gibbs R, Levine R, Giclas P, Salmon J, et al.The interrelationship of complement-activation fragments and angiogenesis-related factors in early pregnancy and theirassociation with pre-eclampsia. BJOG. 2010 Mar;117(4):456-462.

Thadhani R, Hagmann H, Schaarschmidt W, Roth B, Cingoez T, Karumanchi SA, et al.Removal of Soluble Fms-Like Tyrosine Kinase-1 by Dextran Sulfate Apheresis in Preeclampsia. Journal American Society of Nephrology. 2016 Mar;27(3): 903-913.

GunardiJI, Mose J, Handono B, Satari MH, AnwarAD, Fauziah PN, et al. Difference of concentration of placental soluble fms like tyrosine kinase 1(sFlt 1), placental growth factor (PlGF), and sFlt 1/ PlGF ratio in severe preeclampsia and normal pregnancy. BMC Res Notes.2015 Oct;8:534.

Pinheiro CC, Rayol P, Gozzani L, dos Reis LM, Zampieri G, Dias CB, et al. The relationship of angiogenic factors to maternal and neonatal manifestations of early-onset and late-onset preeclampsia. Prenatal Diagnosis.2014 Nov;34(11):1084–1092.

Kwiatkowski S, Dołęgowska B, Ewa K, Rzepka R, Natalia, Marczuk BL, Torbe WMB. Do the physiological aging of the placenta and thechanges in angiogenesis marker sFlt-1 and PlGF concentrations predispose patients to late-onset preeclampsia? The Journal of Maternal-Fetal & Neonatal Medicine.2017 Agus.1-10.

Roberts JM, Bell MJ. If we know so much about preeclampsia, why haven't we cured the disease? J Reprod Immunol.2013 Sep;99(1-2):1-9.

Orabona R, Vizzardi E, Sciatti E, Prefumo F, Bonade I, Valcamonico A, et al. Maternal cardiac function after HELLP syndrome: an echocardiographic study. Ultrasound Obstet Gynecol.2017 Oct;50(4):507-513.

Bahado-Singh RO, Syngelmortality rate in Indonesia A, Akolekar R, Mandal R, BjondahlTC, Han B, et al.Validation of metabolomic models for prediction of early-onset preeclampsia. American Journal of Obstetrics & Gynecology.2015 Oct;213(4):530.

Weel, I. C., Baergen, R. N., Romão-Veiga, M., Borges, V. T., Ribeiro, V. R., Witkin, S. S., et al. Association between Placental Lesions, Cytokines and Angiogenic Factors in Pregnant Women with Preeclampsia. PLOS ONE. 2016 Jun;11(4):1-15.